Cubicin News
Most Popular Cubicin Story
ALSO NOTED: Alexza gains $50M; AstraZeneca, Cubist sign $10.25M licensing pact; and much more...
> Symphony Capital Partners will provide $50 million to Alexza Pharmaceuticals for the development of AZ-002 and AZ-004, both of which are in Phase II trials. Release
> Shanghai-based Cathay Industrial Biotech has closed a $52 million second round of financing. Investors include Goldman Sachs, Gramineae Holdings Company Limited, GM Investment Company Limited and New Horizon Evergreen Investment. …
... Read more...Latest Headlines
- June 27, 2005
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
